Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3032-3042

  Friberg, Lena E ^a   Ravva, Patanjali ^b   Karlsson, Mats O ^a   Liu, Ping ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORICONAZOLE;

ARTICLE; CHILD; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EXPOSURE; FEMALE; HUMAN; IMMUNOCOMPROMISED PATIENT; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MICHAELIS MENTEN KINETICS; NONLINEAR SYSTEM; OPTIMAL DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MODELS, THEORETICAL; PYRIMIDINES; TRIAZOLES;

EID: 84861142646     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05761-11     Document Type: Article

References (16)

1. Andes D, Marchillo K, Stamstad T, Conklin R. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169. (Pubitemid 37229574)
2. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Predictioncorrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13:143-151.
3. Clancy CJ, Nguyen MH. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575. (Pubitemid 28464363)
4. Driscoll TA, et al. 2011. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob. Agents Chemother. 55:5780-5789.
5. Driscoll TA, et al. 2011. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob. Agents Chemother. 55:5770-5779.
6. Espinel-Ingroff A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202. (Pubitemid 28047458)
7. Espinel-Ingroff A, Boyle K, Sheehan DJ. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115. (Pubitemid 32623880)
8. Karlsson MO, Lutsar I, Milligan PA. 2009. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob. Agents Chemother. 53:935-944.
9. Karlsson MO, Savic RM. 2007. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82:17-20. (Pubitemid 46944205)
10. Michael C, et al. 2010. Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. Antimicrob. Agents Chemother. 54:3225-3232.
11. Perfect JR, et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131. (Pubitemid 36549632)
12. .Petersson KJ, Hanze E, Savic RM, Karlsson MO. 2009. Semiparametric distributions with estimated shape parameters. Pharm. Res. 26:2174-2185.
13. Pfizer. 2010. VFEND (voriconazole) package insert. Pfizer Inc., New York, NY.
14. Scott LJ, Simpson D. 2007. Voriconazole: a review of its use in the management of invasive fungal infections. Drugs 67:269-298.
15. Walsh TJ, et al. 2010. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob. Agents Chemother. 54:4116-4123.
16. Walsh TJ, et al. 2004. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. 48:2166-2172. Friberg et al. (Pubitemid 38691615)